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Background. Recent work indicates that comprehensive genomic sequencing can 
be a highly effective tool in defining the transmission of microbial pathogens. We have 
studied the utility of the routine use of genomic sequencing for infection control sur-
veillance in an academic medical center.
Methods. The genomes of inpatient and emergency department isolates 
of Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, and 
Enterococcus faecium were sequenced. Within each species, single-nucleotide polymor-
phisms (SNP) were identified in the core genome for all isolates using alignment-based 
methods. The number of SNP differences between isolate pairs was determined and 
used, in combination with the patient’s electronic medical records to identify potential 
transmission events.
Results. Between September 2016 and March 2017, 388 S. aureus, 66 P. aerugi-
nosa, 48 K. pneumoniae, and 29 E. faecium isolates were sequenced from 373 patients. 
There was variation in the distribution of SNP differences between intrapatient iso-
lates for the four pathogens; with the least variability for E.  faecium and greatest for 
P. aeruginosa. The majority of the bacterial isolates from separate patients appeared 
to be genetically unique exhibiting marked SNP differences from other isolates. There 
were 19 sets of isolates where the SNP variation between interpatient isolates was either 
comparable to that of intrapatient variation (12) and suggestive of recent transmission 
events, or with SNP variation somewhat greater than the intrapatient SNP variation (7) 
suggesting relative relatedness. Only one of the highly related sets had been previously 
identified by standard infection control surveillance. Likely transmissions appeared 
to have occurred both in the inpatient and outpatient settings, and the transmission 
routes were not always apparent.
Conclusion. The routine use of genomic sequencing analysis identified previously 
unrecognized likely transmission events within the institution’s patient population that 
are of relevance to infection control surveillance. This capacity should significantly 
enhance our understanding of the epidemiology of hospital acquired infections, and 
assist in developing and implementing new prevention strategies.
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Background. We recently mitigated a clonal outbreak of Mycobacterium absces-
sus, including a large cluster of patients who developed invasive infection after expos-
ure to heater-cooler units (HCU) during cardiac surgery. Recent studies have described 
a small number of Mycobacterium chimera infections linked to open-heart surgery; 
however, little is known about the epidemiology and clinical courses of cardiac sur-
gery patients with invasive infection from rapidly-growing mycobacteria, such as 
M. abscessus.
Methods. We retrospectively collected clinical data from all patients who under-
went cardiac surgery at our hospital and had positive cultures for M. abscessus from 
2013 to 2016. We excluded heart transplant recipients and patients who at time of 
diagnosis had ventricular assist devices. We analyzed patient characteristics, antibiotic 
treatment courses, surgical interventions, and clinical outcomes.
Results. Nine cardiac surgery patients who met the case definition developed 
culture-proven invasive infection from M. abscessus (Figure 1). Seven (78%) infec-
tions occurred after surgeries that included valve replacement. Median time from 
suspected inoculation in the operating room to first positive culture was 49 days 
(interquartile range, 38–115  days). Seven (78%) patients had bloodstream infec-
tions, and six (67%) patients had sternal wound infections. Six (67%) patients devel-
oped disseminated disease with infection at multiple sites. All patients received 
combination antimicrobial therapy. The most common majority regimen (n  =  6) 
was imipenem, amikacin, and tigecycline. Four (44%) patients experienced thera-
py-limiting antibiotic toxicities (Figure 2). Seven (78%) patients were well enough 
to undergo at least one surgical debridement. Five (56%) patients stopped therapy 
due to presumed cure, but four (44%) patients had deaths attributable to M. absces-
sus infection.
Conclusion. Invasive M. abscessus infection after cardiac surgery was associated 
with high morbidity and mortality. Most patients underwent surgical debridement 
and received prolonged three-drug antimicrobial therapy, which was complicated by 
numerous antibiotic toxicities. Treatment cured five patients, but four patients died 
from mycobacterial disease.
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Background. Universal decolonization with daily chlorhexidine (CHG) bathing 
with and without nasal decolonization has significantly reduced positive MRSA clin-
ical cultures and bloodstream infections in adult ICUs in several clinical trials. We 
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evaluated whether decolonization was similarly effective in a lower risk hospitalized 
population.
Methods. We conducted a 2 arm cluster-randomized trial involving a 1-year 
baseline period (April 2013–March 2014) and a 21-month intervention period (June 
2014–February 2016). All noncritical care units in a hospital were assigned to the same 
strategy. These were (1) Routine Care: routine bathing product and frequency and (2) 
Decolonization: CHG for routine daily bathing (2% leave-on CHG) or showering (4% 
rinse-off CHG) for all patients plus mupirocin for 5 days for known MRSA. Universal 
ICU decolonization was in place in both arms by September 2013. Differences between 
the arms in the outcome rates between the baseline and intervention periods were 
assessed with proportional hazards models, using shared frailties to account for clus-
tering by hospital. The primary analysis was as-randomized and unadjusted. Primary 
outcome was any MRSA or VRE clinical isolate attributable to the unit. Secondary 
outcome was all-cause bloodstream infections. Additional analyses adjusted for age, 
gender, race, Medicaid insurer, surgery, and comorbidities.
Results. We randomized 53 hospitals in 15 states. There were 194 adult units with 
189,616 admissions in the baseline period and 340,350 in the intervention period. 
Common unit types included mixed medical surgical (30%), cardiac (20%), step-down 
(11%), medical (10%), surgical (10%), and oncology (4%). There were no significant 
differences between arms in the relative hazards for intervention vs. baseline for either 
outcome (Table and Figure). Adjusted analyses yielded similar results.
Conclusion. Universal daily CHG bathing or showering plus targeted mupirocin 
for MRSA+ patients in non-critical care units did not reduce the combination of pos-
itive MRSA and VRE clinical cultures or bloodstream infections due to all pathogens. 
Further analyses to assess for any differential effects in high-risk subpopulations will 
be important.
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Background. RSV is the most common cause of lower respiratory tract infec-
tion (LRTI) among infants making prevention of RSV disease a public health priority. 
A significant unmet need exists for RSV prevention in healthy infants. Our goal is to 
develop a mAb with an extended half-life (t½) capable of protecting infants for an entire 
RSV season by using a single intramuscular (IM) dose. This study was conducted to 
evaluate the safety profile, pharmacokinetics (PK), RSV neutralizing antibody titers, 
and anti-drug antibody (ADA) responses for MEDI8897 in healthy preterm infants 
born between 32 and 35 weeks gestational age.
Methods. Infants were randomized 4:1 to receive a single IM injection of 
MEDI8897 10 mg (n  =  8), 25 mg (n  =  31), 50 mg (n  =  32) or placebo (n  =  18) and 
followed for 360 days. Enrollment occurred during the 2,015 RSV seasons in the US, 
South Africa, and Chile. Blood was collected at multiple timepoints. Infants who met 
criteria for a medically-attended (MA) LRTI had nasal swabs obtained for RSV testing 
by RT-PCR.
Results. A  total of 85/89 (95.5%) infants completed the study. Adverse events 
(AEs) were reported in 17/18 (94.4%) placebo and 66/71 (93.0%) MEDI8897 recip-
ients. Five serious AEs (three LRTIs, two febrile seizures) were reported in three 
MEDI8897 recipients. No events were consistent with hypersensitivity reactions. The 
estimated MEDI8897 serum t½ ranged from 62.5 to 72.9 days. On day 151, 87% of the 
infants who received the 50 mg dose of MEDI8897 had serum concentrations above the 
target EC90 level of 6.8 µg/ml, and 93.3% showed a ≥3-fold rise from baseline in serum 
anti-RSV neutralizing antibody titers. ADA was detected in 28.2% of MEDI8897 recip-
ients, but when present was not associated with any safety findings. ADA was detected 
at day 361 only in 26.5% of subjects. MA-LRTI was reported in 5 (7%) MEDI8897 
recipients through 150 days after dosing. The one subject with an MA-LRTI caused by 
RSV had received a 10 mg dose of MEDI8897.
Conclusion. In healthy preterm infants, the safety profile of MEDI8897 was 
favorable. The extended t½ of MEDI8897 with the corresponding increase in RSV 
neutralizing antibody levels was confirmed and supports protection from RSV disease 
during a typical 5-month season with a single 50 mg IM dose.
This study was sponsored by MedImmune.
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Background. RSV is the leading cause of hospitalization for bronchiolitis in 
infants and young children worldwide. Second-hand smoke (SHS) exposure has 
been associated with increased morbidity in children with respiratory infections. The 
objectives of this study were to explore the association between SHS measured by hair 
nicotine and disease severity in infants with RSV infection, and to define its impact on 
the blood transcriptional immune profiles.
Methods. Single-center, prospective study of previously healthy infants pre-
senting to the Emergency Department with RSV bronchiolitis with and without SHS 
exposure assessed by hair nicotine levels. Exclusion criteria included: prematurity; 
chronic medical conditions, and insufficient hair. Clinical outcomes were assessed 
using a clinical disease severity score (CDSS; ranging from 0 to 15) and care provided 
(hospitalization and intensive care). Blood samples from patients and healthy controls 
were obtained at enrollment for gene expression profiling, and differences in profiles 
stratified by SHS exposure.
Results. A total of 70 infants with RSV were enrolled (median age 2.7 months; 
44 (62.8%) males; 44 (62.8%) white). Hair nicotine was detected in 45 (64.2%) 
infants with RSV while 25 RSV+ infants had undetectable hair nicotine levels. 
Demographic variables were not significantly different between SHS exposed and 
nonexposed infants. Median nicotine concentrations in infants with severe (CDSS 
>10) vs. mild RSV disease (CDSS < 5) were 5.3 and 2.1 ng/mg (P = 0.49). In addition, 
blood transcriptional profiles in RSV infants exposed to SHS vs. nonexposed, were 
characterized by significantly greater overexpression of genes related to inflamma-
tion, apoptosis and cell death, and greater suppression of T and B cell-related genes 
(Figure 1).
Conclusion. In otherwise healthy infants with RSV infection exposure to SHS was 
associated with greater inflammation and blunted T and B cell responses. Although not 
statistically significant, hair nicotine levels were higher in patients with more severe 
RSV bronchiolitis.
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Background. Weight gain commonly occurs among HIV-infected (HIV+) adults 
initiating modern ART regimens, and obesity is increasingly reported in this popula-
tion. However, data regarding specific risk factors for obesity development after ART 
initiation are conflicting.
Methods. We retrospectively analyzed data from a cohort of HIV+ adults who 
initiated ART between January 1, 2000 and December 31, 2015 in Rio de Janeiro, 
Brazil. Body mass index (BMI) was assessed at ART initiation. Participants who were 
non-obese (BMI < 30 kg/m2) at baseline and had ≥90 days of ART exposure were fol-
lowed for development of obesity. Participants were censored at the time of obesity 
diagnosis or at end of follow-up (defined as death, loss to follow-up, end of study 
period or 2 years after their last weight measurement). Incidence rates were estimated 
using Poisson regression models and risk factor assessment was calculated using Cox 
regression models accounting for death and loss to follow-up as competing risks.
Results. Participants (n = 1,794) were 61.3% male, 48.3% white and had a median 
age of 36.3 years. At ART initiation, participants had a median BMI of 22.6 kg/m2 and 
BMI category distribution was: underweight 14%, normal weight 56%, overweight 22% 
and obese 8%. Of the 1,567 non-obese participants followed after ART initiation, 76% 
gained weight, 44% increased their BMI category and 18% developed obesity. Median 
